Eiger BioPharmaceuticals Inc
(NASDAQ:EIGR)
$2.15
At close: Feb 2
$2.11
-0.0400[-1.86%]
PreMarket: 8:00AM EDT
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Eiger BioPharmaceuticals Stock (NASDAQ:EIGR), Quotes and News Summary

Eiger BioPharmaceuticals Stock (NASDAQ: EIGR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range0.960 - 10.021Open / Close- / -Float / Outstanding36.568M / 44.074M
Vol / Avg.2.252K / 998.529KMkt Cap94.760MP/E-50d Avg. Price2.030
Div / Yield (Forward)- / -%Payout Ratio-Total Float36.568MEPS-2.400
Seeking Alpha - Dec 28, 2022, 1:00PM
Seeking Alpha - Nov 26, 2022, 2:58AM
Sector: Health Care.Industry: Biotechnology
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-09
REV
Q3 2022Est.ActualSurprise
EPS-0.520-0.620 -0.1000
REV4.270M4.024M-246.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Eiger BioPharmaceuticals (EIGR) stock?

A

You can purchase shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Eiger BioPharmaceuticals's (EIGR) competitors?

Q

What is the target price for Eiger BioPharmaceuticals (EIGR) stock?

A

The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by BTIG on Wednesday, September 7, 2022. The analyst firm set a price target for 48.00 expecting EIGR to rise to within 12 months (a possible 2132.56% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Eiger BioPharmaceuticals (EIGR)?

A

The stock price for Eiger BioPharmaceuticals (NASDAQ: EIGR) is $2.15 last updated February 2, 2023 at 9:00 PM UTC.

Q

Does Eiger BioPharmaceuticals (EIGR) pay a dividend?

A

There are no upcoming dividends for Eiger BioPharmaceuticals.

Q

When is Eiger BioPharmaceuticals (NASDAQ:EIGR) reporting earnings?

A

Eiger BioPharmaceuticals’s Q4 earnings are confirmed for Thursday, March 9, 2023.

Q

Is Eiger BioPharmaceuticals (EIGR) going to split?

A

There is no upcoming split for Eiger BioPharmaceuticals.

Q

What sector and industry does Eiger BioPharmaceuticals (EIGR) operate in?

A

Eiger BioPharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.